{"subsection_name": null, "pub_date": "2011-10-20T14:24:35Z", "byline": {"original": "By BRUCE JAPSEN", "person": [{"lastname": "JAPSEN", "organization": "", "rank": 1, "role": "reported", "firstname": "Bruce"}]}, "abstract": "In the third quarter, Abbott's Niaspan failed to show the double-digit sales increases that the drug had previously generated.", "word_count": 399, "print_page": null, "news_desk": null, "snippet": "In the third quarter, Abbott's Niaspan failed to show the double-digit sales increases that the drug had previously generated.", "multimedia": [], "source": "The New York Times", "blog": [], "keywords": [{"name": "type_of_material", "value": "News", "rank": "1"}, {"name": "organizations", "value": "National Institutes of Health", "rank": "3"}, {"name": "subject", "value": "Cholesterol", "rank": "2"}], "type_of_material": "Blog", "lead_paragraph": "New Abbott sales data shows that physicians are reconsidering whether to prescribe a drug used to raise levels of good cholesterol after a study earlier this year questioned whether it reduced the risk of heart attacks.", "web_url": "http://prescriptions.blogs.nytimes.com/2011/10/20/cholesterol-drug-sales-slip-after-study/", "section_name": "Health", "headline": {"main": "Cholesterol Drug Sales Slip After Study", "kicker": "Prescriptions"}, "slideshow_credits": null, "_id": "4fd3a1458eb7c8105d8e7c1d", "document_type": "blogpost"}